Incontinence Home > VESIcare and Breastfeeding

Since no studies have been conducted on the link between VESIcare and breastfeeding in humans, it is not known whether the drug passes through breast milk. The medication has been shown to pass through breast milk in mice, however. Thus, be sure to watch for any side effects in your child if you are taking VESIcare and breastfeeding (or thinking about breastfeeding).

Is VESIcare Safe While Breastfeeding?

At this time, it is not known whether VESIcare® (solifenacin succinate) passes through breast milk in women. The manufacturer recommends that women avoid taking the drug while breastfeeding.

VESIcare and Breastfeeding: What Does the Research Say?

Studies have shown that VESIcare passes through breast milk in mice. However, no studies have been conducted to determine if it also passes through breast milk in humans. If your healthcare provider recommends that you take VESIcare while breastfeeding, be sure to watch for any side effects in your infant.

Talking With Your Healthcare Provider About VESIcare and Breastfeeding

You should talk with your healthcare provider about VESIcare and breastfeeding. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision about VESIcare and breastfeeding that is right for you.
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation




Related Channels

eMedTV Links
Copyright © 2006-2019 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.